A

AFT Pharmaceuticals Ltd
NZX:AFT

Watchlist Manager
AFT Pharmaceuticals Ltd
NZX:AFT
Watchlist
Price: 2.84 NZD 1.43% Market Closed
Market Cap: 297.8m NZD
Have any thoughts about
AFT Pharmaceuticals Ltd?
Write Note

Operating Margin
AFT Pharmaceuticals Ltd

9.7%
Current
12%
Average
6.8%
Industry

Operating Margin represents how efficiently a company is able to generate profit through its core operations.

Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.

Operating Margin
9.7%
=
Operating Profit
19.2m
/
Revenue
198.5m

Operating Margin Across Competitors

Country Company Market Cap Operating
Margin
NZ
AFT Pharmaceuticals Ltd
NZX:AFT
297.8m NZD
10%
JP
Nichi-Iko Pharmaceutical Co Ltd
TSE:4541
776 550.9T JPY
-83%
US
Eli Lilly and Co
NYSE:LLY
750.9B USD
35%
UK
Dechra Pharmaceuticals PLC
LSE:DPH
440.4B GBP
3%
DK
Novo Nordisk A/S
CSE:NOVO B
2.8T DKK
44%
US
Johnson & Johnson
NYSE:JNJ
346.5B USD
28%
US
Merck & Co Inc
NYSE:MRK
250.3B USD
34%
CH
Roche Holding AG
SIX:ROG
199.5B CHF
32%
UK
AstraZeneca PLC
LSE:AZN
161.2B GBP
21%
CH
Novartis AG
SIX:NOVN
171.3B CHF
31%
US
Pfizer Inc
NYSE:PFE
149.9B USD
22%
Country NZ
Market Cap 297.8m NZD
Operating Margin
10%
Country JP
Market Cap 776 550.9T JPY
Operating Margin
-83%
Country US
Market Cap 750.9B USD
Operating Margin
35%
Country UK
Market Cap 440.4B GBP
Operating Margin
3%
Country DK
Market Cap 2.8T DKK
Operating Margin
44%
Country US
Market Cap 346.5B USD
Operating Margin
28%
Country US
Market Cap 250.3B USD
Operating Margin
34%
Country CH
Market Cap 199.5B CHF
Operating Margin
32%
Country UK
Market Cap 161.2B GBP
Operating Margin
21%
Country CH
Market Cap 171.3B CHF
Operating Margin
31%
Country US
Market Cap 149.9B USD
Operating Margin
22%
No Stocks Found

AFT Pharmaceuticals Ltd
Glance View

Market Cap
297.8m NZD
Industry
Pharmaceuticals

AFT Pharmaceuticals Ltd. engages in the development, licensing, and distribution of medical and pharmaceutical products. The firm's segments include New Zealand, Australia, Asia and Rest of World. The firm's products include Crystaderm, Maxigesic, Coco-scalp, Maxiclear, RestoraNail and Myconail, among others. The firm's NasoSURF Nebuliser is in pilot scale production. The firm is focused on conducting clinical for Maxigesic oral dose forms. The firm is also conducting clinical trials of Maxigesic intravenous (IV). Maxigesic PE is a cold and flu variant. Its subsidiary, AFT Pharmaceuticals (AU) Pty Ltd, is engaged in distribution of pharmaceuticals in Australia. Its subsidiary, AFT Pharmaceuticals Singapore Pte Ltd, is engaged in the registration of pharmaceuticals in Singapore. Its subsidiary, AFT Pharmaceuticals (S.E. Asia) Sdn Bhd, is engaged in the distribution of pharmaceuticals in Malaysia.

AFT Intrinsic Value
4.72 NZD
Undervaluation 40%
Intrinsic Value
Price
A

See Also

Discover More
What is Operating Margin?

Operating Margin represents how efficiently a company is able to generate profit through its core operations.

Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.

Operating Margin
9.7%
=
Operating Profit
19.2m
/
Revenue
198.5m
What is the Operating Margin of AFT Pharmaceuticals Ltd?

Based on AFT Pharmaceuticals Ltd's most recent financial statements, the company has Operating Margin of 9.7%.